Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMPION-MG: Ravulizumab in Generalized Myasthenia Gravis
NCT03920293Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Started Mar 2019; status: completed.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03920293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920293.